Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The Burden of Opioid-Related Adverse Drug Events on Hospitalized Previously Opioid-Free Surgical Patients.

Urman RD, Seger DL, Fiskio JM, Neville BA, Harry EM, Weiner SG, Lovelace B, Fain R, Cirillo J, Schnipper JL.

J Patient Saf. 2019 Jan 21. doi: 10.1097/PTS.0000000000000566. [Epub ahead of print]

PMID:
30672762
2.

Analysis of predictors of opioid-free analgesia for management of acute post-surgical pain in the United States.

Urman RD, Böing EA, Khangulov V, Fain R, Nathanson BH, Wan GJ, Lovelace B, Pham AT, Cirillo J.

Curr Med Res Opin. 2019 Feb;35(2):283-289. doi: 10.1080/03007995.2018.1481376. Epub 2018 Jun 26.

PMID:
29799282
3.

Improved Outcomes Associated With the Use of Intravenous Acetaminophen for Management of Acute Post-Surgical Pain in Cesarean Sections and Hysterectomies.

Urman RD, Boing EA, Pham AT, Khangulov V, Fain R, Nathanson BH, Zhang X, Wan GJ, Lovelace B, Cirillo J.

J Clin Med Res. 2018 Jun;10(6):499-507. doi: 10.14740/jocmr3380w. Epub 2018 Apr 13.

4.

Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.

Nabavizadeh N, Waller JG, Fain R 3rd, Chen Y, Degnin CR, Elliott DA, Mullins BT, Patel IA, Dyer BA, Fakhoury K, Naugler WE, Farsad K, Tanyi JA, Fuss M, Thomas CR Jr, Hung AY.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):577-585. doi: 10.1016/j.ijrobp.2017.11.030. Epub 2017 Nov 27.

PMID:
29413273
5.

Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects.

Raffa RB, Pawasauskas J, Pergolizzi JV Jr, Lu L, Chen Y, Wu S, Jarrett B, Fain R, Hill L, Devarakonda K.

Clin Drug Investig. 2018 Mar;38(3):259-268. doi: 10.1007/s40261-017-0610-4.

6.

Evaluation of near-miss and adverse events in radiation oncology using a comprehensive causal factor taxonomy.

Spraker MB, Fain R 3rd, Gopan O, Zeng J, Nyflot M, Jordan L, Kane G, Ford E.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):346-353. doi: 10.1016/j.prro.2017.05.008.

PMID:
28865683
7.

Photonic Needles for Light Delivery in Deep Tissue-like Media.

Fain R, Barbosa F, Cardenas J, Lipson M.

Sci Rep. 2017 Jul 17;7(1):5627. doi: 10.1038/s41598-017-05746-7.

8.

Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.

Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, Fujioka K, Aronne LJ.

Obesity (Silver Spring). 2017 May;25(5):857-865. doi: 10.1002/oby.21811.

9.

Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus.

Magkos F, Nikonova E, Fain R, Zhou S, Ma T, Shanahan W.

Obesity (Silver Spring). 2017 May;25(5):842-849. doi: 10.1002/oby.21798. Epub 2017 Mar 27.

10.

Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.

Weissman NJ, Smith SR, Fain R, Hall N, Shanahan WR.

Obesity (Silver Spring). 2017 Jan;25(1):39-44. doi: 10.1002/oby.21695. Epub 2016 Nov 26.

11.

Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies.

Leppik IE, Yang H, Williams B, Zhou S, Fain R, Patten A, Bibbiani F, Laurenza A.

Epilepsia. 2017 Jan;58(1):51-59. doi: 10.1111/epi.13600. Epub 2016 Nov 21.

12.

Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.

Handelsman Y, Fain R, Wang Z, Li X, Fujioka K, Shanahan W.

Postgrad Med. 2016 Nov;128(8):740-746. Epub 2016 Oct 19.

PMID:
27659698
13.

Safety and tolerability review of lorcaserin in clinical trials.

Greenway FL, Shanahan W, Fain R, Ma T, Rubino D.

Clin Obes. 2016 Oct;6(5):285-95. doi: 10.1111/cob.12159. Review.

PMID:
27627785
14.

Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.

Pi-Sunyer X, Shanahan W, Fain R, Ma T, Garvey WT.

Postgrad Med. 2016 Aug;128(6):591-7. doi: 10.1080/00325481.2016.1208618. Epub 2016 Jul 18.

PMID:
27389084
15.

Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.

Nguyen CT, Zhou S, Shanahan W, Fain R.

Clin Ther. 2016 Jun;38(6):1498-1509. doi: 10.1016/j.clinthera.2016.04.004. Epub 2016 May 17.

PMID:
27206567
16.

Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.

Apovian C, Palmer K, Fain R, Perdomo C, Rubino D.

Diabetes Obes Metab. 2016 Sep;18(9):945-8. doi: 10.1111/dom.12690. Epub 2016 Jun 22.

PMID:
27173586
17.

Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.

Nesto R, Fain R, Li Y, Shanahan W.

Postgrad Med. 2016 May;128(4):364-70. doi: 10.1080/00325481.2016.1178590.

PMID:
27116910
18.

Shoulder Pain After Definitive Lung Radiotherapy.

Fain R 3rd, Thomas CR Jr, Nabavizadeh N.

JAMA Oncol. 2016 Apr;2(4):537-8. doi: 10.1001/jamaoncol.2015.6591. No abstract available.

PMID:
26892853
19.

Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.

Glauser T, Laurenza A, Yang H, Williams B, Ma T, Fain R.

Epilepsy Res. 2016 Jan;119:34-40. doi: 10.1016/j.eplepsyres.2015.11.014. Epub 2015 Dec 1.

20.

Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.

Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A.

Epilepsia. 2015 Aug;56(8):1252-63. doi: 10.1111/epi.13054. Epub 2015 Jul 3.

21.

Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.

Montouris G, Yang H, Williams B, Zhou S, Laurenza A, Fain R.

Epilepsy Res. 2015 Aug;114:131-40. doi: 10.1016/j.eplepsyres.2015.04.011. Epub 2015 May 1.

22.

Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.

Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, Kumar D, Ferry J.

Neurology. 2015 May 12;84(19):1972-80. doi: 10.1212/WNL.0000000000001558. Epub 2015 Apr 15.

23.

Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.

Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, Williams B, Kumar D, Zhu J, Laurenza A.

Eur J Paediatr Neurol. 2015 Jul;19(4):435-45. doi: 10.1016/j.ejpn.2015.02.008. Epub 2015 Mar 5.

24.

Silicon-chip mid-infrared frequency comb generation.

Griffith AG, Lau RK, Cardenas J, Okawachi Y, Mohanty A, Fain R, Lee YH, Yu M, Phare CT, Poitras CB, Gaeta AL, Lipson M.

Nat Commun. 2015 Feb 24;6:6299. doi: 10.1038/ncomms7299.

PMID:
25708922
25.

On the use (and misuse?) of the Edinburgh Handedness Inventory.

Edlin JM, Leppanen ML, Fain RJ, Hackländer RP, Hanaver-Torrez SD, Lyle KB.

Brain Cogn. 2015 Mar;94:44-51. doi: 10.1016/j.bandc.2015.01.003. Epub 2015 Feb 2. Review.

PMID:
25656540
26.

ABFM's self-assessment module (SAM) revision process.

Hagen MD, Quan MA, Fain R, DeBord W.

Ann Fam Med. 2015 Jan-Feb;13(1):88-9. doi: 10.1370/afm.1745. No abstract available.

27.

Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.

Aronne L, Shanahan W, Fain R, Glicklich A, Soliman W, Li Y, Smith S.

Postgrad Med. 2014 Oct;126(6):7-18. doi: 10.3810/pgm.2014.10.2817.

PMID:
25414931
28.

Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.

Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K, Fain R, Shanahan WR.

Obesity (Silver Spring). 2014 Oct;22(10):2137-46. doi: 10.1002/oby.20841. Epub 2014 Jul 18. Erratum in: Obesity (Silver Spring). 2014 Dec;22(12):2641.

29.

The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.

Gidal BE, Majid O, Ferry J, Hussein Z, Yang H, Zhu J, Fain R, Laurenza A.

Epilepsy Behav. 2014 Jun;35:6-12. doi: 10.1016/j.yebeh.2014.03.013. Epub 2014 Apr 27.

PMID:
24785428
30.

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R.

BMC Geriatr. 2013 Jun 6;13:56. doi: 10.1186/1471-2318-13-56.

31.

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity.

Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R.

Alzheimers Res Ther. 2013 Feb 21;5(1):12. doi: 10.1186/alzrt166. eCollection 2013.

32.

Ubisol-Aqua: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model.

Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ.

Curr HIV Res. 2010 Apr;8(3):232-9.

PMID:
20158454
33.

Role of endogenous ET-1 in the regulation of myocardial blood flow in lean and obese humans.

Mather KJ, Lteif AA, Veeneman E, Fain R, Giger S, Perry K, Hutchins GD.

Obesity (Silver Spring). 2010 Jan;18(1):63-70. doi: 10.1038/oby.2009.196. Epub 2009 Jun 18.

34.

Wealth from Health: an incentive program for disease and population management: a 12-year project.

Ratner D, Louria D, Sheffet A, Fain R, Curran J, Saed N, Bhaskar S, Quereshi M, Cable G.

Lippincotts Case Manag. 2001 Sep-Oct;6(5):184-204.

PMID:
16398037
35.

Usefulness of positron emission tomography in predicting long-term outcome in patients with diabetes mellitus and ischemic left ventricular dysfunction.

Sawada S, Hamoui O, Barclay J, Giger S, Fain R, Foltz J, Fineberg N, Hutchins G.

Am J Cardiol. 2005 Jul 1;96(1):2-8.

PMID:
15979422
36.

Effect of naloxone on perceived exertion and exercise capacity during maximal cycle ergometry.

Sgherza AL, Axen K, Fain R, Hoffman RS, Dunbar CC, Haas F.

J Appl Physiol (1985). 2002 Dec;93(6):2023-8. Epub 2002 Aug 23.

37.

Positron emission tomography in cochlear implant and auditory brain stem implant recipients.

Miyamoto RT, Wong D, Pisoni DB, Hutchins G, Sehgal M, Fain R.

Am J Otol. 1999 Sep;20(5):596-601.

38.

Cardiac sympathetic denervation after transmyocardial laser revascularization.

Al-Sheikh T, Allen KB, Straka SP, Heimansohn DA, Fain RL, Hutchins GD, Sawada SG, Zipes DP, Engelstein ED.

Circulation. 1999 Jul 13;100(2):135-40.

PMID:
10402442
39.

PET imaging of oxidative metabolism abnormalities in sympathetically denervated canine myocardium.

Hutchins GD, Chen T, Carlson KA, Fain RL, Winkle W, Vavrek T, Mock BH, Zipes DP.

J Nucl Med. 1999 May;40(5):846-53.

40.

Disaster, stress and the doctor.

Fain RM, Schreier RA.

Med Educ. 1989 Jan;23(1):91-6.

PMID:
2927348
41.

Psychological functioning following an acute disaster.

Barling J, Bluen SD, Fain R.

J Appl Psychol. 1987 Nov;72(4):683-90. No abstract available.

PMID:
3119558
42.

Little league shoulder: rotational stress fracture of proximal epiphysis.

Tullos HS, Fain RH.

J Sports Med. 1974 May-Jun;2(3):152-3. No abstract available.

PMID:
4468328
43.

Little league shoulder: lesions of the proximal humeral epiphyseal plate.

Cahill BR, Tullos HS, Fain RH.

J Sports Med. 1974 May-Jun;2(3):150-2. No abstract available.

PMID:
4468327
44.

Isolated sublaxation of the carpal scaphoid associated with secondary displacement of the capitate.

Tullos HS, Erwin WD, Fain RH.

South Med J. 1973 May;66(5):568-74. No abstract available.

PMID:
4698766
45.

Lesions of the feet in athletes.

King JW, Tullos H, Stanley R, Fain R, Brelsford HJ.

South Med J. 1971 Jan;64(1):45-8. No abstract available.

PMID:
4993329

Supplemental Content

Support Center